Cargando…

Characterization of the mechanism by which the RB/E2F pathway controls expression of the cancer genomic DNA deaminase APOBEC3B

APOBEC3B (A3B)-catalyzed DNA cytosine deamination contributes to the overall mutational landscape in breast cancer. Molecular mechanisms responsible for A3B upregulation in cancer are poorly understood. Here we show that a single E2F cis-element mediates repression in normal cells and that expressio...

Descripción completa

Detalles Bibliográficos
Autores principales: Roelofs, Pieter A, Goh, Chai Yeen, Chua, Boon Haow, Jarvis, Matthew C, Stewart, Teneale A, McCann, Jennifer L, McDougle, Rebecca M, Carpenter, Michael A, Martens, John WM, Span, Paul N, Kappei, Dennis, Harris, Reuben S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: eLife Sciences Publications, Ltd 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7553775/
https://www.ncbi.nlm.nih.gov/pubmed/32985974
http://dx.doi.org/10.7554/eLife.61287
_version_ 1783593671214497792
author Roelofs, Pieter A
Goh, Chai Yeen
Chua, Boon Haow
Jarvis, Matthew C
Stewart, Teneale A
McCann, Jennifer L
McDougle, Rebecca M
Carpenter, Michael A
Martens, John WM
Span, Paul N
Kappei, Dennis
Harris, Reuben S
author_facet Roelofs, Pieter A
Goh, Chai Yeen
Chua, Boon Haow
Jarvis, Matthew C
Stewart, Teneale A
McCann, Jennifer L
McDougle, Rebecca M
Carpenter, Michael A
Martens, John WM
Span, Paul N
Kappei, Dennis
Harris, Reuben S
author_sort Roelofs, Pieter A
collection PubMed
description APOBEC3B (A3B)-catalyzed DNA cytosine deamination contributes to the overall mutational landscape in breast cancer. Molecular mechanisms responsible for A3B upregulation in cancer are poorly understood. Here we show that a single E2F cis-element mediates repression in normal cells and that expression is activated by its mutational disruption in a reporter construct or the endogenous A3B gene. The same E2F site is required for A3B induction by polyomavirus T antigen indicating a shared molecular mechanism. Proteomic and biochemical experiments demonstrate the binding of wildtype but not mutant E2F promoters by repressive PRC1.6/E2F6 and DREAM/E2F4 complexes. Knockdown and overexpression studies confirm the involvement of these repressive complexes in regulating A3B expression. Altogether, these studies demonstrate that A3B expression is suppressed in normal cells by repressive E2F complexes and that viral or mutational disruption of this regulatory network triggers overexpression in breast cancer and provides fuel for tumor evolution.
format Online
Article
Text
id pubmed-7553775
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher eLife Sciences Publications, Ltd
record_format MEDLINE/PubMed
spelling pubmed-75537752020-10-14 Characterization of the mechanism by which the RB/E2F pathway controls expression of the cancer genomic DNA deaminase APOBEC3B Roelofs, Pieter A Goh, Chai Yeen Chua, Boon Haow Jarvis, Matthew C Stewart, Teneale A McCann, Jennifer L McDougle, Rebecca M Carpenter, Michael A Martens, John WM Span, Paul N Kappei, Dennis Harris, Reuben S eLife Cancer Biology APOBEC3B (A3B)-catalyzed DNA cytosine deamination contributes to the overall mutational landscape in breast cancer. Molecular mechanisms responsible for A3B upregulation in cancer are poorly understood. Here we show that a single E2F cis-element mediates repression in normal cells and that expression is activated by its mutational disruption in a reporter construct or the endogenous A3B gene. The same E2F site is required for A3B induction by polyomavirus T antigen indicating a shared molecular mechanism. Proteomic and biochemical experiments demonstrate the binding of wildtype but not mutant E2F promoters by repressive PRC1.6/E2F6 and DREAM/E2F4 complexes. Knockdown and overexpression studies confirm the involvement of these repressive complexes in regulating A3B expression. Altogether, these studies demonstrate that A3B expression is suppressed in normal cells by repressive E2F complexes and that viral or mutational disruption of this regulatory network triggers overexpression in breast cancer and provides fuel for tumor evolution. eLife Sciences Publications, Ltd 2020-09-28 /pmc/articles/PMC7553775/ /pubmed/32985974 http://dx.doi.org/10.7554/eLife.61287 Text en © 2020, Roelofs et al http://creativecommons.org/licenses/by/4.0/ http://creativecommons.org/licenses/by/4.0/This article is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use and redistribution provided that the original author and source are credited.
spellingShingle Cancer Biology
Roelofs, Pieter A
Goh, Chai Yeen
Chua, Boon Haow
Jarvis, Matthew C
Stewart, Teneale A
McCann, Jennifer L
McDougle, Rebecca M
Carpenter, Michael A
Martens, John WM
Span, Paul N
Kappei, Dennis
Harris, Reuben S
Characterization of the mechanism by which the RB/E2F pathway controls expression of the cancer genomic DNA deaminase APOBEC3B
title Characterization of the mechanism by which the RB/E2F pathway controls expression of the cancer genomic DNA deaminase APOBEC3B
title_full Characterization of the mechanism by which the RB/E2F pathway controls expression of the cancer genomic DNA deaminase APOBEC3B
title_fullStr Characterization of the mechanism by which the RB/E2F pathway controls expression of the cancer genomic DNA deaminase APOBEC3B
title_full_unstemmed Characterization of the mechanism by which the RB/E2F pathway controls expression of the cancer genomic DNA deaminase APOBEC3B
title_short Characterization of the mechanism by which the RB/E2F pathway controls expression of the cancer genomic DNA deaminase APOBEC3B
title_sort characterization of the mechanism by which the rb/e2f pathway controls expression of the cancer genomic dna deaminase apobec3b
topic Cancer Biology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7553775/
https://www.ncbi.nlm.nih.gov/pubmed/32985974
http://dx.doi.org/10.7554/eLife.61287
work_keys_str_mv AT roelofspietera characterizationofthemechanismbywhichtherbe2fpathwaycontrolsexpressionofthecancergenomicdnadeaminaseapobec3b
AT gohchaiyeen characterizationofthemechanismbywhichtherbe2fpathwaycontrolsexpressionofthecancergenomicdnadeaminaseapobec3b
AT chuaboonhaow characterizationofthemechanismbywhichtherbe2fpathwaycontrolsexpressionofthecancergenomicdnadeaminaseapobec3b
AT jarvismatthewc characterizationofthemechanismbywhichtherbe2fpathwaycontrolsexpressionofthecancergenomicdnadeaminaseapobec3b
AT stewarttenealea characterizationofthemechanismbywhichtherbe2fpathwaycontrolsexpressionofthecancergenomicdnadeaminaseapobec3b
AT mccannjenniferl characterizationofthemechanismbywhichtherbe2fpathwaycontrolsexpressionofthecancergenomicdnadeaminaseapobec3b
AT mcdouglerebeccam characterizationofthemechanismbywhichtherbe2fpathwaycontrolsexpressionofthecancergenomicdnadeaminaseapobec3b
AT carpentermichaela characterizationofthemechanismbywhichtherbe2fpathwaycontrolsexpressionofthecancergenomicdnadeaminaseapobec3b
AT martensjohnwm characterizationofthemechanismbywhichtherbe2fpathwaycontrolsexpressionofthecancergenomicdnadeaminaseapobec3b
AT spanpauln characterizationofthemechanismbywhichtherbe2fpathwaycontrolsexpressionofthecancergenomicdnadeaminaseapobec3b
AT kappeidennis characterizationofthemechanismbywhichtherbe2fpathwaycontrolsexpressionofthecancergenomicdnadeaminaseapobec3b
AT harrisreubens characterizationofthemechanismbywhichtherbe2fpathwaycontrolsexpressionofthecancergenomicdnadeaminaseapobec3b